What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? It depends on how you measure it

Metabolism: Clinical and Experimental

Volumn 60, Issue 1, 2011, Pages 57-62

  Abbasi, Fahim ^a   Lamendola, Cindy ^a   Reaven, Gerald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; OCTREOTIDE; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SUPPRESSION TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 78649909201     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.02.015     Document Type: Article

References (15)

1. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., and Jones N.P. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
2. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
3. Saltiel A.R., and Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 45 1996 1661 1669
4. Stumvoll M., and Haring H.U. Glitazones: clinical effects and molecular mechanisms Ann Med 34 2002 217 224
5. Kim S.H., Abbasi F., Chu J.W., McLaughlin T.L., Lamendola C., and Polonsky K.S. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals Diabetes 54 2005 2447 2452
6. Pei D., Jones C.N., Bhargava R., Chen Y.D., and Reaven G.M. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test Diabetologia 37 1994 843 845
7. Shen S.W., Reaven G.M., and Farquhar J.W. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes J Clin Invest 49 1970 2151 2160
8. Greenfield M.S., Doberne L., Kraemer F., Tobey T., and Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp Diabetes 30 1981 387 392
9. Yip J., Facchini F.S., and Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease J Clin Endocrinol Metab 83 1998 2773 2776
10. Facchini F.S., Hua N., Abbasi F., and Reaven G.M. Insulin resistance as a predictor of age-related diseases J Clin Endocrinol Metab 86 2001 3574 3578
11. Abbasi F., Chu J.W., McLaughlin T., Lamendola C., Leary E.T., and Reaven G.M. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus Metabolism 53 2004 159 164
12. Mifflin M.D., St Jeor S.T., Hill L.A., Scott B.J., Daugherty S.A., and Koh Y.O. A new predictive equation for resting energy expenditure in healthy individuals Am J Clin Nutr 51 1990 241 247
13. Kahn S.E. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes J Clin Endocrinol Metab 86 2001 4047 4058
14. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 237 1979 E214 223
15. Byrne M.M., Sturis J., and Polonsky K.S. Insulin secretion and clearance during low-dose graded glucose infusion Am J Physiol 268 1995 E21 E27